Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Seyedmahdi Pahlavani"'
Autor:
Yaşar Çalışkan, Seyedmahdi Pahlavani, Ariel Schnell, Aliza Anwar Memon, Fadee Abu Al Rub, Usama Elewa, Marie Philipneri, Kana Miyata, Thanh-Mai Vo, Amy Mosman, Thomas Groll, John C. Edwards, Krista L. Lentine
Publikováno v:
Turkish Journal of Nephrology, Vol 31, Iss 3, Pp 230-236 (2022)
Externí odkaz:
https://doaj.org/article/0394176dbc6b405b96f59b6cf83d0157
Autor:
Mathieu Kerneis, Gregory Y.H. Lip, Roxana Mehran, Tarek Nafee, Jonathan L. Halperin, Keith A.A. Fox, Christoph Bode, Seyedmahdi Pahlavani, Freek W.A. Verheugt, Marc Cohen, Peter Wildgoose, Gerald Chi, Mahshid Mir, C. Michael Gibson, Usama Talib, Martin van Eickels, Fahad AlKhalfan, Eric D. Peterson
Publikováno v:
JACC: Cardiovascular Interventions. 11:626-634
Objectives This study sought to assess whether there were significant interactions of procedural access strategies and lesion characteristics with bleeding and ischemic events among atrial fibrillation (AF) patients anticoagulated with rivaroxaban or
Autor:
Mahshid, Talebi-Taher, Ladan, Abbasian, Seiedeh Nina, Alavi-Niakou, Seied Ali, Javad-Moosavi, Seyedmahdi, Pahlavani
Publikováno v:
Tanaffos
Background: The risk of tuberculosis (TB) is greater for individuals with human immunodeficiency virus (HIV) who are on combined antiretroviral therapy (c-ART) than for the normal population. Therefore, the detection and treatment of latent tuberculo
Autor:
Gerald Chi, Zahra Karimi, Farima Kahe, Mehrian Jafarizade, Seyedmahdi Pahlavani, Adeel Jamil, Arzu Kalayci
Supported by evidence from basic science, clinical, and epidemiological studies, the high-density lipoprotein (HDL) hypothesis posits that reduction in HDL levels may accelerate the development of coronary heart disease (CHD). HDL may also exert card
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f85a8b72c3ef3d4caaa411c0ff81a6
Autor:
Yazan Daaboul, Anmol Pitliya, Mathieu Kerneis, C. Michael Gibson, Seyedmahdi Pahlavani, Hassan A Kazmi, Sudarshana Datta, Muhammad Furqan, Tarek Nafee, Ahmed Younes, Usama Talib
Publikováno v:
Progress in cardiovascular diseases. 60(4-5)
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percutaneous coronary intervention (PCI). However, approximately 10% of these patients have concomitant atrial fibrillation (AF) and requir
Autor:
Umer Jamil, Muhammad A. Balouch, Mehrian Jafarizade, Seyedmahdi Pahlavani, Miroslav Radulovic, Gerald Chi, Jolanta Marszalek, Arzu Kalayci, Zahra Karimi, Sunny Kumar, Husnain Shaukat, Adeel Jamil
Publikováno v:
Medical hypotheses. 114
The concurrence of atrial fibrillation and acute coronary syndrome poses a conundrum in the antithrombotic management as intensification of anticoagulation or antiplatelet therapy inevitably comes at the price of an increased bleeding risk. Various a
Autor:
Mathieu, Kerneis, C Michael, Gibson, Gerald, Chi, Roxana, Mehran, Fahad, AlKhalfan, Usama, Talib, Seyedmahdi, Pahlavani, Mahshid, Mir, Christoph, Bode, Jonathan L, Halperin, Tarek, Nafee, Eric D, Peterson, Freek W A, Verheugt, Peter, Wildgoose, Martin, van Eickels, Gregory Y H, Lip, Keith A A, Fox, Marc, Cohen
Publikováno v:
JACC. Cardiovascular interventions. 11(7)
This study sought to assess whether there were significant interactions of procedural access strategies and lesion characteristics with bleeding and ischemic events among atrial fibrillation (AF) patients anticoagulated with rivaroxaban or warfarin f
Autor:
Yazan Daaboul, Aysha Aslam, C. Michael Gibson, Aravind Reddy Kuchkuntla, Dima Nimri, Anthony Gallo, Gerald Chi, Seyedmahdi Pahlavani, Tarek Nafee, Serge Korjian, Nathan Michalak, Usama Talib
Publikováno v:
Expert review of cardiovascular therapy. 15(4)
Andexanet alfa is a recombinant factor Xa decoy molecule that inhibits direct and indirect factor Xa inhibitors to allow the normal coagulation process to resume. Its development arises in a space where novel oral anticoagulants are receiving expande
Autor:
Jolanta Marszalek, Seyedmahdi Pahlavani, Adeel Jamil, Zahra Karimi, Gerald Chi, James J. Peters, Miroslav Radulovic, Usama Talib, Sara Mehrsefat, Umer Jamil, Michela Faggioni
Publikováno v:
Journal of the American College of Cardiology. 71:A38
Dual antiplatelet therapy (DAPT) has been the mainstay of antithrombotic management for acute coronary syndrome (ACS). Approximately 5-10% of patients experience recurrent events despite standard treatment, and there is an unmet demand for secondary